Deutsche Bank says the Spanish economy will keep outpacing the euro area’s growth after inflation and borrowing costs eased https://t.co/yPWiFtO3ps ...

Core Insights - Nxera Pharma will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals due to the initiation of clinical development of ORX142, a novel orexin receptor 2 (OX2R) agonist [1][2] - The milestone payments include US$1.8 million recognized as revenue in Q2 2025 and US$3.0 million in Q3 2025 [2] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet medical needs in Japan and globally [3] - The company has established a commercial business in Japan to develop and market innovative medicines, addressing a growing market in the APAC region [3] Pipeline and Development - Nxera Pharma has an extensive pipeline of over 30 active programs, utilizing its NxWave™ discovery platform, targeting major unmet needs in neurology, metabolic diseases, and immunology [4] - The pipeline includes potentially first- and best-in-class candidates, advancing from discovery to late clinical stages in collaboration with leading pharmaceutical and biotech companies [4] Workforce and Locations - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [5]

Well, I mean, look, what what are the Chinese going to say. And and by the way, it's a complete fallacy. Uh they have a non-convertible currency. So, how are they going to be a reserve currency.Uh they also have 1.4% billion people who want to get their money out of China. They have capital constraints on taking out taking out money. The uh sin kuan for reserve currency is that it trades freely.And I saw uh my friend Christian Lagard, president of the ECB the other day said that maybe this is the Euro's mom ...

Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** Equasens Group (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 mo ...

You're walking into a grand library, one with endless shelves far past your eyes can see. Each book holds a piece of history, a story that shaped the world. Some books shine under the glaring lights of the library, stories that have been told time and time again.Other stories, dark, worn, dust covered, sit unread. Now imagine there's a librarian choosing which books are directly accessible in front of you and which books are tucked away into the shadows. Who gets to decide which stories we remember. And mor ...

ECB officials highlighted potential dangers for exporters from gains in the euro https://t.co/z6STD8MXt4 ...

Switzerland and Germany agree to jointly purchase multiple ground-based air defense systems as part of the European Sky Shield Initiative https://t.co/X41nexCV4R ...

Nearly 11 million people in the Netherlands will switch to a new retirement plan from January 2026, as the country embarks on a pension overhaul that’s expected to spur volatility across European bond markets https://t.co/SnIsFqfoor ...

Genius™ “designed to mimic natural intelligence”VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) ("VERSES'' or the "Company”), a cognitive computing company specializing in next-generation agentic software systems, has been featured in Psychology Today. “VERSES AI’s Genius model is different,” said Grant Hilary Brenner MD, (Distinguished Fellow of the American Psychiatric Association) in the article, “Developed by computational psychiatrist Karl Frist ...

Governor, when you look at some of the concerns, of course, regarding what we're going to do at the ECB, like how do you see the ECB in a good place in terms of inflation for the moment. We are in a good place, but there is no reason for complacency. There are risks that are two sided.First of all, the trade war. Tariffs for is creating risks to the upside. But even more, we see risks to the downside in a sense that our own projection is indicating that inflation is likely to be below target for 18 months.A ...